PhaseWell RESEARCH

CASE STUDY / PHASEWELL ONCOLOGY

From first meeting to greenlight in *43 days.*

A Top 5 pharma sponsor's global multiple myeloma program was enrolling slower than expected. A PhaseWell Oncology site went from site selection to activation in 24 days, against a 193-day average at other U.S. sites, and consented its first patient three days later.

START-UP

43 days
Initial meeting to ready to enroll

24 days
Selection to activation, vs. a 193-day U.S. average

EXECUTION

3 days
Site activation to first patient consented

5-day
eCRF entry SLA, with minimal deviations

THE CHALLENGE

A narrow patient population, and a global program behind schedule.

The sponsor needed U.S. sites that could activate quickly and find eligible patients right away, in a population few sites see in volume.

Hard-to-find patients
Eligibility required heavily pretreated relapsed or refractory multiple myeloma, a narrow population few sites see in volume.

Enrollment falling behind
The narrow patient profile had slowed enrollment across the program.

Slow U.S. start-up
Other activated U.S. sites averaged 193 days from site selection to activation.

STUDY SNAPSHOT

SPONSOR	INDICATION	PHASE	SITE
Top 5 pharma	Relapsed / refractory multiple myeloma	Phase III · global program	Gabrail Research, Part of PhaseWell Oncology

WHAT DROVE SUCCESS

Start-up run as a sprint, and patient finding ready on day one.

Start-up treated as a shared project

Weekly meetings with the sponsor and a highly responsive team kept every start-up task moving, from first conversation to greenlight in 43 days. IRB, CTA and budget, and the regulatory packet all ran in parallel.

Patients found inside the practice

Established processes with the site's affiliated oncology practice flagged potentially eligible patients already in care, backed by dedicated on-site staff.

Technology-assisted chart review

Technology accelerated chart review, so the team could find the few patients who met the criteria quickly.

Outreach beyond the practice

Community talks, physician referral relationships and digital campaigns widened the pool beyond existing patients.

Data the sponsor could rely on

A 5-day eCRF entry SLA, fast query response and formalized deviation controls kept data clean from the first patient.

THE OUTCOME

What it meant for the sponsor.

> *Your speed, precision, and professionalism made this rapid activation possible.*

STUDY SPONSOR

U.S. capacity when the program needed it

Fast activation gave a program behind on enrollment an early U.S. foothold, with 3 patients enrolled at the site.

A relationship built to last

Exceptional data quality reinforced the sponsor's confidence, and the sponsor has since awarded follow-on studies.

Planning your next oncology study?

Let's talk about how fast we can get your trial started.

BD@PHASEWELL.COM